J&J Says 30,000-40,000 Patients Are On Standby For Cypher Approval
This article was originally published in The Gray Sheet
Executive Summary
Interventional cardiologists are delaying a significant number of conventional stenting procedures as they anticipate near-term FDA approval of Johnson & Johnson's sirolimus-eluting Cypher stent